Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 249

1.

HDAC inhibition induces HIV-1 protein and enables immune-based clearance following latency reversal.

Wu G, Swanson M, Talla A, Graham D, Strizki J, Gorman D, Barnard RJ, Blair W, Søgaard OS, Tolstrup M, Østergaard L, Rasmussen TA, Sekaly RP, Archin NM, Margolis DM, Hazuda DJ, Howell BJ.

JCI Insight. 2017 Aug 17;2(16). pii: 92901. doi: 10.1172/jci.insight.92901. [Epub ahead of print]

2.

Identification of proximal biomarkers of PKC agonism and evaluation of their role in HIV reactivation.

Vemula SV, Maxwell JW, Nefedov A, Wan BL, Steve J, Newhard W, Sanchez RI, Tellers D, Barnard RJ, Blair W, Hazuda D, Webber AL, Howell BJ.

Antiviral Res. 2017 Mar;139:161-170. doi: 10.1016/j.antiviral.2016.11.014. Epub 2016 Nov 23.

PMID:
27889530
3.

A Novel Assay to Measure the Magnitude of the Inducible Viral Reservoir in HIV-infected Individuals.

Procopio FA, Fromentin R, Kulpa DA, Brehm JH, Bebin AG, Strain MC, Richman DD, O'Doherty U, Palmer S, Hecht FM, Hoh R, Barnard RJ, Miller MD, Hazuda DJ, Deeks SG, Sékaly RP, Chomont N.

EBioMedicine. 2015 Jun 27;2(8):874-83. doi: 10.1016/j.ebiom.2015.06.019. eCollection 2015 Aug.

4.

Association between first-year virological response to raltegravir and long-term outcomes in treatment-experienced patients with HIV-1 infection.

Eron JJ, Cooper DA, Steigbigel RT, Clotet B, Yeni P, Strohmaier KM, Rodgers AJ, Barnard RJ, Nguyen BY, Teppler H; BENCHMRK Study Teams.

Antivir Ther. 2015;20(3):307-15. doi: 10.3851/IMP2912. Epub 2014 Oct 27.

5.

Virologic resistance analysis from a phase 2 study of MK-5172 combined with pegylated interferon/ribavirin in treatment-naive patients with hepatitis C virus genotype 1 infection.

Howe AY, Black S, Curry S, Ludmerer SW, Liu R, Barnard RJ, Newhard W, Hwang PM, Nickle D, Gilbert C, Caro L, DiNubile MJ, Mobashery N.

Clin Infect Dis. 2014 Dec 15;59(12):1657-65. doi: 10.1093/cid/ciu696. Epub 2014 Sep 28.

PMID:
25266289
6.

Impact of diet and exercise on lipid management in the modern era.

Franklin BA, Durstine JL, Roberts CK, Barnard RJ.

Best Pract Res Clin Endocrinol Metab. 2014 Jun;28(3):405-21. doi: 10.1016/j.beem.2014.01.005. Epub 2014 Jan 22. Review.

PMID:
24840267
7.

Combination of vaniprevir with peginterferon and ribavirin significantly increases the rate of SVR in treatment-experienced patients with chronic HCV genotype 1 infection and cirrhosis.

Rodriguez-Torres M, Stoehr A, Gane EJ, Serfaty L, Lawitz E, Zhou A, Bourque M, Bhanja S, Strizki J, Barnard RJ, Hwang PM, DiNubile MJ, Mobashery N.

Clin Gastroenterol Hepatol. 2014 Jun;12(6):1029-37.e5. doi: 10.1016/j.cgh.2013.09.067. Epub 2013 Oct 10.

PMID:
24120953
8.

Effects of an intensive short-term diet and exercise intervention: comparison between normal-weight and obese children.

Roberts CK, Izadpanah A, Angadi SS, Barnard RJ.

Am J Physiol Regul Integr Comp Physiol. 2013 Sep;305(5):R552-7. doi: 10.1152/ajpregu.00131.2013. Epub 2013 Jul 24.

9.

Analysis of boceprevir resistance associated amino acid variants (RAVs) in two phase 3 boceprevir clinical studies.

Barnard RJ, Howe JA, Ogert RA, Zeuzem S, Poordad F, Gordon SC, Ralston R, Tong X, Sniukiene V, Strizki J, Ryan D, Long J, Qiu P, Brass CA, Albrecht J, Burroughs M, Vuocolo S, Hazuda DJ.

Virology. 2013 Sep;444(1-2):329-36. doi: 10.1016/j.virol.2013.06.029. Epub 2013 Jul 19.

10.

Emergence of resistance-associated variants after failed triple therapy with vaniprevir in treatment-experienced non-cirrhotic patients with hepatitis C-genotype 1 infection: a population and clonal analysis.

Barnard RJ, McHale CM, Newhard W, Cheney CA, Graham DJ, Himmelberger AL, Strizki J, Hwang PM, Rivera AA, Reeves JD, Nickle D, Dinubile MJ, Hazuda DJ, Mobashery N.

Virology. 2013 Sep 1;443(2):278-84. doi: 10.1016/j.virol.2013.05.013. Epub 2013 Jun 10.

11.

Metabolic syndrome and insulin resistance: underlying causes and modification by exercise training.

Roberts CK, Hevener AL, Barnard RJ.

Compr Physiol. 2013 Jan;3(1):1-58. doi: 10.1002/cphy.c110062. Review.

12.

Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trials.

Eron JJ, Cooper DA, Steigbigel RT, Clotet B, Gatell JM, Kumar PN, Rockstroh JK, Schechter M, Markowitz M, Yeni P, Loutfy MR, Lazzarin A, Lennox JL, Strohmaier KM, Wan H, Barnard RJ, Nguyen BY, Teppler H; BENCHMRK Study Teams.

Lancet Infect Dis. 2013 Jul;13(7):587-96. doi: 10.1016/S1473-3099(13)70093-8. Epub 2013 May 7.

PMID:
23664333
13.

Antiviral activity of boceprevir monotherapy in treatment-naive subjects with chronic hepatitis C genotype 2/3.

Silva MO, Treitel M, Graham DJ, Curry S, Frontera MJ, McMonagle P, Gupta S, Hughes E, Chase R, Lahser F, Barnard RJ, Howe AY, Howe JA.

J Hepatol. 2013 Jul;59(1):31-7. doi: 10.1016/j.jhep.2013.02.018. Epub 2013 Feb 27.

PMID:
23454058
14.

A phase 2B study of MK-7009 (vaniprevir) in patients with genotype 1 HCV infection who have failed previous pegylated interferon and ribavirin treatment.

Lawitz E, Rodriguez-Torres M, Stoehr A, Gane EJ, Serfaty L, Bhanja S, Barnard RJ, An D, Gress J, Hwang P, Mobashery N.

J Hepatol. 2013 Jul;59(1):11-7. doi: 10.1016/j.jhep.2013.02.008. Epub 2013 Feb 21.

PMID:
23439259
15.

Resistance-associated amino acid variants associated with boceprevir plus pegylated interferon-α2b and ribavirin in patients with chronic hepatitis C in the SPRINT-1 trial.

Ogert RA, Howe JA, Vierling JM, Kwo PY, Lawitz EJ, McCone J, Schiff ER, Pound D, Davis MN, Gordon SC, Ravendhran N, Rossaro L, Jacobson IM, Ralston R, Chaudhri E, Qiu P, Pedicone LD, Brass CA, Albrecht JK, Barnard RJ, Hazuda DJ, Howe AY.

Antivir Ther. 2013;18(3):387-97. doi: 10.3851/IMP2549. Epub 2013 Feb 13.

PMID:
23406826
16.

A short-term diet and exercise intervention ameliorates inflammation and markers of metabolic health in overweight/obese children.

Izadpanah A, Barnard RJ, Almeda AJ, Baldwin GC, Bridges SA, Shellman ER, Burant CF, Roberts CK.

Am J Physiol Endocrinol Metab. 2012 Aug 15;303(4):E542-50. doi: 10.1152/ajpendo.00190.2012. Epub 2012 Jun 19.

17.

Effect of a low-fat diet combined with IGF-1 receptor blockade on 22Rv1 prostate cancer xenografts.

Konijeti R, Koyama S, Gray A, Barnard RJ, Said JW, Castor B, Elashoff D, Wan J, Beltran PJ, Calzone FJ, Cohen P, Galet C, Aronson WJ.

Mol Cancer Ther. 2012 Jul;11(7):1539-46. doi: 10.1158/1535-7163.MCT-11-1003. Epub 2012 May 4.

18.

Vaniprevir with pegylated interferon alpha-2a and ribavirin in treatment-naïve patients with chronic hepatitis C: a randomized phase II study.

Manns MP, Gane E, Rodriguez-Torres M, Stoehr A, Yeh CT, Marcellin P, Wiedmann RT, Hwang PM, Caro L, Barnard RJ, Lee AW; MK-7009 Protocol 007 Study Group.

Hepatology. 2012 Sep;56(3):884-93. doi: 10.1002/hep.25743. Epub 2012 Jul 17.

PMID:
22473713
19.

Pharmacodynamic analysis of a serine protease inhibitor, MK-4519, against hepatitis C virus using a novel in vitro pharmacodynamic system.

Brown AN, McSharry JJ, Adams JR, Kulawy R, Barnard RJ, Newhard W, Corbin A, Hazuda DJ, Louie A, Drusano GL.

Antimicrob Agents Chemother. 2012 Mar;56(3):1170-81. doi: 10.1128/AAC.05383-11. Epub 2011 Dec 12.

20.

Phase II prospective randomized trial of a low-fat diet with fish oil supplementation in men undergoing radical prostatectomy.

Aronson WJ, Kobayashi N, Barnard RJ, Henning S, Huang M, Jardack PM, Liu B, Gray A, Wan J, Konijeti R, Freedland SJ, Castor B, Heber D, Elashoff D, Said J, Cohen P, Galet C.

Cancer Prev Res (Phila). 2011 Dec;4(12):2062-71. doi: 10.1158/1940-6207.CAPR-11-0298. Epub 2011 Oct 25.

21.

Global Igfbp1 deletion does not affect prostate cancer development in a c-Myc transgenic mouse model.

Gray A, Aronson WJ, Barnard RJ, Mehta H, Wan J, Said J, Cohen P, Galet C.

J Endocrinol. 2011 Dec;211(3):297-304. doi: 10.1530/JOE-11-0240. Epub 2011 Sep 8.

22.

Raltegravir versus Efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses.

Lennox JL, Dejesus E, Berger DS, Lazzarin A, Pollard RB, Ramalho Madruga JV, Zhao J, Wan H, Gilbert CL, Teppler H, Rodgers AJ, Barnard RJ, Miller MD, Dinubile MJ, Nguyen BY, Leavitt R, Sklar P; STARTMRK Investigators.

J Acquir Immune Defic Syndr. 2010 Sep;55(1):39-48. doi: 10.1097/QAI.0b013e3181da1287. Erratum in: J Acquir Immune Defic Syndr. 2011 Dec 1;58(4):e120. Dosage error in article text.

PMID:
20404738
23.

Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials.

Steigbigel RT, Cooper DA, Teppler H, Eron JJ, Gatell JM, Kumar PN, Rockstroh JK, Schechter M, Katlama C, Markowitz M, Yeni P, Loutfy MR, Lazzarin A, Lennox JL, Clotet B, Zhao J, Wan H, Rhodes RR, Strohmaier KM, Barnard RJ, Isaacs RD, Nguyen BY; BENCHMRK Study Teamsa.

Clin Infect Dis. 2010 Feb 15;50(4):605-12. doi: 10.1086/650002.

PMID:
20085491
24.

Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials.

Eron JJ, Young B, Cooper DA, Youle M, Dejesus E, Andrade-Villanueva J, Workman C, Zajdenverg R, Fätkenheuer G, Berger DS, Kumar PN, Rodgers AJ, Shaughnessy MA, Walker ML, Barnard RJ, Miller MD, Dinubile MJ, Nguyen BY, Leavitt R, Xu X, Sklar P; SWITCHMRK 1 and 2 investigators.

Lancet. 2010 Jan 30;375(9712):396-407. doi: 10.1016/S0140-6736(09)62041-9. Epub 2010 Jan 12.

PMID:
20074791
25.

Benign prostatic hyperplasia: does lifestyle play a role?

Barnard RJ, Aronson WJ.

Phys Sportsmed. 2009 Dec;37(4):141-6. doi: 10.3810/psm.2009.12.1752. Review.

PMID:
20048551
26.

Growth inhibitory effect of low fat diet on prostate cancer cells: results of a prospective, randomized dietary intervention trial in men with prostate cancer.

Aronson WJ, Barnard RJ, Freedland SJ, Henning S, Elashoff D, Jardack PM, Cohen P, Heber D, Kobayashi N.

J Urol. 2010 Jan;183(1):345-50. doi: 10.1016/j.juro.2009.08.104.

27.

Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial.

Lennox JL, DeJesus E, Lazzarin A, Pollard RB, Madruga JV, Berger DS, Zhao J, Xu X, Williams-Diaz A, Rodgers AJ, Barnard RJ, Miller MD, DiNubile MJ, Nguyen BY, Leavitt R, Sklar P; STARTMRK investigators.

Lancet. 2009 Sep 5;374(9692):796-806. doi: 10.1016/S0140-6736(09)60918-1. Epub 2009 Aug 3. Erratum in: Lancet. 2009 Dec 19-2010 Jan 1;374(9707):2054. Lancet. 2009 Sep 5;374(9692):786.

PMID:
19647866
28.

Analyzing serum-stimulated prostate cancer cell lines after low-fat, high-fiber diet and exercise intervention.

Soliman S, Aronson WJ, Barnard RJ.

Evid Based Complement Alternat Med. 2011;2011:529053. doi: 10.1093/ecam/nep031. Epub 2011 Mar 15.

29.

Weight loss with a low-carbohydrate, Mediterranean, or low-fat diet.

Roberts CK, Barnard RJ, Croymans DM.

N Engl J Med. 2008 Nov 13;359(20):2169; author reply 2171-2. doi: 10.1056/NEJMc081747. No abstract available.

30.

Effect of low-fat diet on development of prostate cancer and Akt phosphorylation in the Hi-Myc transgenic mouse model.

Kobayashi N, Barnard RJ, Said J, Hong-Gonzalez J, Corman DM, Ku M, Doan NB, Gui D, Elashoff D, Cohen P, Aronson WJ.

Cancer Res. 2008 Apr 15;68(8):3066-73. doi: 10.1158/0008-5472.CAN-07-5616.

31.

Effect of diet and exercise intervention on the growth of prostate epithelial cells.

Barnard RJ, Kobayashi N, Aronson WJ.

Prostate Cancer Prostatic Dis. 2008;11(4):362-6. doi: 10.1038/pcan.2008.6. Epub 2008 Feb 19.

PMID:
18283296
32.

Prostate cancer prevention by nutritional means to alleviate metabolic syndrome.

Barnard RJ.

Am J Clin Nutr. 2007 Sep;86(3):s889-93. Review.

PMID:
18265484
33.

Monitoring the development of non-nucleoside reverse transcriptase inhibitor-associated resistant HIV-1 using an electrochemiluminescence-based reverse transcriptase polymerase assay.

Munshi V, Lu M, Felock P, Barnard RJ, Hazuda DJ, Miller MD, Lai MT.

Anal Biochem. 2008 Mar 1;374(1):121-32. Epub 2007 Oct 9.

PMID:
17964275
34.

A mechanism to explain how regular exercise might reduce the risk for clinical prostate cancer.

Barnard RJ, Leung PS, Aronson WJ, Cohen P, Golding LA.

Eur J Cancer Prev. 2007 Oct;16(5):415-21.

PMID:
17923812
35.

Relationship of dietary protein and soy isoflavones to serum IGF-1 and IGF binding proteins in the Prostate Cancer Lifestyle Trial.

Dewell A, Weidner G, Sumner MD, Barnard RJ, Marlin RO, Daubenmier JJ, Chi C, Carroll PR, Ornish D.

Nutr Cancer. 2007;58(1):35-42.

PMID:
17571965
36.

Monosynaptic restriction of transsynaptic tracing from single, genetically targeted neurons.

Wickersham IR, Lyon DC, Barnard RJ, Mori T, Finke S, Conzelmann KK, Young JA, Callaway EM.

Neuron. 2007 Mar 1;53(5):639-47.

37.

Effect of a short-term diet and exercise intervention in youth on atherosclerotic risk factors.

Roberts CK, Chen AK, Barnard RJ.

Atherosclerosis. 2007 Mar;191(1):98-106. Epub 2006 Oct 19.

PMID:
17054960
38.
39.

Effect of a short-term diet and exercise intervention on inflammatory/anti-inflammatory properties of HDL in overweight/obese men with cardiovascular risk factors.

Roberts CK, Ng C, Hama S, Eliseo AJ, Barnard RJ.

J Appl Physiol (1985). 2006 Dec;101(6):1727-32. Epub 2006 Aug 10.

40.

Effect of altering dietary omega-6/omega-3 fatty acid ratios on prostate cancer membrane composition, cyclooxygenase-2, and prostaglandin E2.

Kobayashi N, Barnard RJ, Henning SM, Elashoff D, Reddy ST, Cohen P, Leung P, Hong-Gonzalez J, Freedland SJ, Said J, Gui D, Seeram NP, Popoviciu LM, Bagga D, Heber D, Glaspy JA, Aronson WJ.

Clin Cancer Res. 2006 Aug 1;12(15):4662-70.

41.

Phase II study of pomegranate juice for men with rising prostate-specific antigen following surgery or radiation for prostate cancer.

Pantuck AJ, Leppert JT, Zomorodian N, Aronson W, Hong J, Barnard RJ, Seeram N, Liker H, Wang H, Elashoff R, Heber D, Aviram M, Ignarro L, Belldegrun A.

Clin Cancer Res. 2006 Jul 1;12(13):4018-26.

42.

Oxidative stress and dysregulation of NAD(P)H oxidase and antioxidant enzymes in diet-induced metabolic syndrome.

Roberts CK, Barnard RJ, Sindhu RK, Jurczak M, Ehdaie A, Vaziri ND.

Metabolism. 2006 Jul;55(7):928-34.

PMID:
16784966
43.

Effect of a short-term diet and exercise intervention on metabolic syndrome in overweight children.

Chen AK, Roberts CK, Barnard RJ.

Metabolism. 2006 Jul;55(7):871-8.

PMID:
16784957
44.

Tea polyphenols and theaflavins are present in prostate tissue of humans and mice after green and black tea consumption.

Henning SM, Aronson W, Niu Y, Conde F, Lee NH, Seeram NP, Lee RP, Lu J, Harris DM, Moro A, Hong J, Pak-Shan L, Barnard RJ, Ziaee HG, Csathy G, Go VL, Wang H, Heber D.

J Nutr. 2006 Jul;136(7):1839-43.

PMID:
16772446
45.

Effect of a diet and exercise intervention on oxidative stress, inflammation and monocyte adhesion in diabetic men.

Roberts CK, Won D, Pruthi S, Lin SS, Barnard RJ.

Diabetes Res Clin Pract. 2006 Sep;73(3):249-59. Epub 2006 Apr 17.

PMID:
16616795
46.
47.

Effect of a short-term diet and exercise intervention on oxidative stress, inflammation, MMP-9, and monocyte chemotactic activity in men with metabolic syndrome factors.

Roberts CK, Won D, Pruthi S, Kurtovic S, Sindhu RK, Vaziri ND, Barnard RJ.

J Appl Physiol (1985). 2006 May;100(5):1657-65. Epub 2005 Dec 15.

48.

Intensive lifestyle changes may affect the progression of prostate cancer.

Ornish D, Weidner G, Fair WR, Marlin R, Pettengill EB, Raisin CJ, Dunn-Emke S, Crutchfield L, Jacobs FN, Barnard RJ, Aronson WJ, McCormac P, McKnight DJ, Fein JD, Dnistrian AM, Weinstein J, Ngo TH, Mendell NR, Carroll PR.

J Urol. 2005 Sep;174(3):1065-9; discussion 1069-70.

PMID:
16094059
49.

Imaging individual retroviral fusion events: from hemifusion to pore formation and growth.

Melikyan GB, Barnard RJ, Abrahamyan LG, Mothes W, Young JA.

Proc Natl Acad Sci U S A. 2005 Jun 14;102(24):8728-33. Epub 2005 Jun 3.

50.

Prevention of Cancer Through Lifestyle Changes.

Barnard RJ.

Evid Based Complement Alternat Med. 2004 Dec;1(3):233-239. Epub 2004 Oct 6.

Supplemental Content

Loading ...
Support Center